Treatment of pulmonary arterial hypertension (PAH): Updated Recommendations of the Cologne Consensus Conference 2011

International Journal of Cardiology

Volumn 154, Issue SUPPL. 1, 2011, Pages

  Ghofrani, H Ardeschir ^a   Distler, Oliver ^b   Gerhardt, Felix ^c   Gorenflo, Matthias ^d   Grünig, Ekkehard ^e   Haefeli, Walter E ^f   Held, Matthias ^g   Hoeper, Marius M ^h   Kähler, Christian M ⁱ   Kaemmerer, Harald ^j   Klose, Hans ^k   Köllner, Volker ^l   Kopp, Bruno ^m   Mebus, Siegrun ^j   Meyer, Andreas ⁿ   Miera, Oliver ^o   Pittrow, David ^p   Riemekasten, Gabriela ^q   Rosenkranz, Stephan ^c   Schranz, Dietmar ^r   Voswinckel, Robert ^a   Olschewski, Horst ^s   more..

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF COLOGNE   (Germany)

^d Department of Pediatric Cardiology ^*  (Belgium)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g Medical Mission Hospital   (Germany)

^h HANNOVER MEDICAL SCHOOL   (Germany)

ⁱ INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^j TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^k UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^l MediClin Bliestal Clinics   (Germany)

^m Pulmonale Hypertonie EV (Phev)   (Germany)

ⁿ Krankenhaus Maria Hilf Daun   (Germany)

^o DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^p DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^q CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^r JUSTUS LIEBIG UNIVERSITY   (Germany)

^s MEDICAL UNIVERSITY OF GRAZ   (Austria)

more..

Author keywords

Guidelines; Pulmonary arterial hypertension; Treatment

Indexed keywords

AMBRISENTAN; AMLODIPINE; ANTICOAGULANT AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CONTRACEPTIVE AGENT; CYCLOSPORIN; DIGOXIN; DILTIAZEM; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ERYTHROMYCIN; FLUCONAZOLE; GLIBENCLAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; ITRACONAZOLE; KETOCONAZOLE; LOPINAVIR; NIFEDIPINE; PHENPROCOUMON; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTANOID; RITONAVIR; SILDENAFIL; SITAXSENTAN; TADALAFIL; UNINDEXED DRUG; UNIPROST;

ALGORITHM; ALTITUDE; BALLOON ATRIAL SEPTOSTOMY; BLOOD VESSEL REACTIVITY; CARDIOLOGY; CATHETER INFECTION; CHILD HEALTH CARE; CLINICAL ASSESSMENT; CONFERENCE PAPER; CONGENITAL HEART MALFORMATION; CONNECTIVE TISSUE DISEASE; CONSENSUS DEVELOPMENT; DIARRHEA; DISEASE ASSOCIATION; DRUG COMBINATION; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG RECALL; EISENMENGER COMPLEX; ELECTIVE SURGERY; EUROPE; FLUID RETENTION; FLUSHING; FUNCTIONAL STATUS; GERMANY; HEADACHE; HEALTH CARE PLANNING; HEART RIGHT VENTRICLE FAILURE; HEART SURGERY; HEART TRANSPLANTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTENSION; INFLUENZA VACCINATION; JAW PAIN; LIVER TOXICITY; LOW DRUG DOSE; LUNG TRANSPLANTATION; MAXIMUM TOLERATED DOSE; META ANALYSIS (TOPIC); NAUSEA; OXYGEN THERAPY; PATIENT REFERRAL; PEDIATRIC CARDIOLOGY; PERIPHERAL EDEMA; PNEUMOCOCCAL VACCINATION; PORTAL HYPERTENSION; PRACTICE GUIDELINE; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VENO-OCCLUSIVE DISEASE; PULMONOLOGY; SIDE EFFECT; SUPPORT GROUP; SUPRAVENTRICULAR TACHYCARDIA; SYNCOPE; TREATMENT ALGORITHM; TREATMENT INDICATION; TREATMENT RESPONSE; VACCINATION;

FEMALE; GERMANY; HUMANS; HYPERTENSION, PULMONARY; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS; PULMONARY MEDICINE;

EID: 84855374692     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/S0167-5273(11)70490-9     Document Type: Conference Paper

References (67)

1. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30;2493-2537.
2. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Respir J 2009; 34;1219-63.
3. Hoeper MM, Ghofrani HA, Gorenflo M, Grünig E, Schranz D, Rosenkranz S. Diagnostik und Therapie der pulmonalen Hypertonie: Europäische Leitlinien 2009; Pneumologie 2010;64;401-14.
4. Galie N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009;30;394-403.
5. Mereles D, Ehlken N, Kreuscher S, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 2006;114;1482-9. (Pubitemid 44527003)
6. De Man FS, Handoko ML, Groepenhoff H, et al. Effects of exercise training in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2009;34;669-75.
7. Whooley MA, Simon GE. Managing depression in medical outpatients. N Engl J Med 2000;343;1942-50. (Pubitemid 32064789)
8. Ladwig KH, Baumert J, Marten M, et al. Posttraumatic stress symptoms and predicted mortality in patients with implantable cardioverter-defibrillators: Results from the prospective living with an implanted cardioverterdefibrillator study. Arch Gen Psychiatry 2008;65;1324-30.
9. Thamm M, Voswinckel R, Tiede H, Lendeckel F, Grimminger F, Seeger W, Ghofrani HA. Air travel can be safe and well tolerated in patients with clinically stable pulmonary hypertension. Pulm Circ 2011;1:239-43.
10. Tongers J, Schwerdtfeger B, Klein G, et al. Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am Heart J 2007;153;127-32. (Pubitemid 44889238)
11. Krasuski RA, Hart SA, Smith B, Wang A, Harrison JK, Bashore TM. Association of anemia and long-term survival in patients with pulmonary hypertension. Int J Cardiol 2011;150;291-5.
12. Rhodes CJ, Howard LS, Busbridge M, Ashby D, Kondili E, Gibbs SR, Wharton J, Wilkins MR. Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension. J Am Coll Cardiol 2011;58;300-9.
13. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006;47;2049-56.
14. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169;441-7. (Pubitemid 38187114)
15. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334;296-302.
16. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358;1119-23. (Pubitemid 32971843)
17. Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 2008;31;407-14.
18. Galie N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006;114;48-54. (Pubitemid 44305274)
19. Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119;2894-2903.
20. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. N Engl J Med 2005;353;2148-57. (Pubitemid 41653106)
21. Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117;3010-9.
22. Galie N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008;371;2093-2100. (Pubitemid 351902178)
23. Olschewski H, Gomberg-Maitland M. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 2008;31;801-901.
24. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347;322-9. (Pubitemid 34815354)
25. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346;896-903. (Pubitemid 34984638)
26. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165;800-4. (Pubitemid 34229650)
27. Simonneau G, Rubin LJ, Galie N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008;149;521-30.
28. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327;76-81.
29. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111;3105-11. (Pubitemid 40847788)
30. Oudiz RJ, Galie N, Olschewski H, et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54;1971-81.
31. Rubin LJ, Badesh DB, Fleming TR, et al., on behalf of the SUPER-2 Investigators. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: SUPER-2. Chest 2011; May 5 [Epub ahead of print].
32. Hoeper MM, Gall H, Seyfarth HJ, et al. Long-term outcome with intravenous iloprost in pulmonary arterial hypertension. Eur Respir J 2009;34;132-7.
33. McLaughlin VV, Benza RL, Rubin RJ, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, Seeger W. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2010;55;1915-22.
34. Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J. Goaloriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005;26;858-63. (Pubitemid 41632043)
35. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;174;1257-63. (Pubitemid 44924827)
36. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010;122;164-72.
37. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010;122;156-63.
38. Evgenov OV, Pacher P, Schmidt PM et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006;5;755-68. (Pubitemid 44323702)
39. Ghofrani HA, Grimminger F. Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy. Eur Respir Rev 2009;18;35-41.
40. Ghofrani HA, Hoeper MM, Halank M, Meyer FJ, Staehler G, Behr J, Ewert R, Weimann G, Grimminger F, on behalf of the study investigators. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J 2010;36;792-9.
41. Schermuly RT, Dony E, Ghofrani HA et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005;115;2811-21. (Pubitemid 41434408)
42. Perros F, Montani D, Dorfmüller P et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008;178;81-8. (Pubitemid 351919196)
43. Ten Freyhaus H, Dumitrescu D, Berghausen E, Vantler M, Caglayan E, Rosenkranz S. Imatinib mesylate for pulmonary arterial hypertension. Exp Opin Investig Drugs 2011 (in press).
44. Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, Barst RJ, Shapiro S, Golpon H, Toshner M, Grimminger F, Pascoe S. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010b;182;1171-7.
45. Hoeper M, Barst RJ, Galiè N, et al. Imatinib in pulmonary arterial hypertension, a randomized efficacy study (IMPRES). Eur Respir J 2011;38(Suppl) (Abstract).
46. Chau EM, Fan KY, Chow WH. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int J Cardiol 2007;120;301-5. (Pubitemid 47069563)
47. Fernandes SM, Newburger JW, Lang P, Pearson DD, Feinstein JA, Gauvreau K, Landzberg MJ. Usefullness of epoprostenol therapy in the severly ill adolescent/adult with Eisenmenger physiology. Am J Cardiol 2003;91;632-5. (Pubitemid 36263277)
48. Mukhopadhyay S, Sharma M, Ramakrishnan S, Yusuf J, Gupta MD, Bhamri N, Trehan V, Tyagi S. Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study. Circulation 2006;114;1807-10. (Pubitemid 44673355)
49. Mukhopadhyay S, Nathani S, Yusuf J, Shrimal D, Tyagi S. Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger syndrome - a randomized, placebo-controlled, double-blind crossover study. Congenit Heart Dis 2011;6;424-31.
50. Dimopoulos K, Inuzuka R, Goletto S, Giannakoulas G, Swan L, Wort SJ, Gatzoulis MA. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation 2010;121;20-25.
51. Bull TM, Fagan KA, Badesch DB. Pulmonary vascular manifestations of mixed connective tissue disease. Rheum Dis Clin North Am 2005;31;451-64. (Pubitemid 41111548)
52. Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003;62;1088-93. (Pubitemid 37323574)
53. Hoeper MM, Seyfarth HJ, Hoeffken G, et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J 2007;30;1096-1102. (Pubitemid 351194755)
54. Reichenberger F, Voswinckel R, Steveling E, et al. Sildenafil treatment for portopulmonary hypertension. Eur Respir J 2006;28;563-7. (Pubitemid 44794671)
55. Cartin-Ceba R, Swanson K, Iyer V, Wiesner RH, Krowka MJ. Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension. Chest 2011;139:109-14.
56. Halank M, Knudsen L, Seyfarth HJ, Ewert R, Wiedemann B, Kolditz M, Höffken G, Hoeper MM. Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension. Z Gastroenterol 2011;49:1258-62
57. Grannas G, Neipp M, Hoeper MM, et al. Indications for and Outcomes After Combined Lung and Liver Transplantation: A Single-Center Experience on 13 Consecutive Cases. Transplantation 2008;85;524-31.
58. Sitbon O, Lascoux-Combe C, Delfraissy JF, et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008;177:108-13.
59. Degano B, Yaici A, Le Pavec J, Savale L, Jais X, Camara B, Humbert M, Simonneau G, Sitbon O. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur Respir J 2009;33;92-8.
60. Sitbon O, Gressin V, Speich R, Macdonald PS, Opravil M, Cooper DA, Fourme T, Humbert M, Delfraissy JF, Simonneau G. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;170;1212-17. (Pubitemid 39577380)
61. Carlsen J, Kjeldsen K, Gerstorft J. Sildenafil as a successful treatment of otherwise fatal HIV-related pulmonary hypertension. AIDS 2002;16;1568-9. (Pubitemid 34804229)
62. Schumacher YO, Zdebik A, Huonker M, Kreisel W. Sildenafil in HIV-related pulmonary hypertension. AIDS 2001;15;1747-8.
63. Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006. Heart 2009;95;312-7.
64. Moledina S, Hislop AA, Foster H, Schulze-Neick I, Haworth SG. Childhood idiopathic pulmonary arterial hypertension: a national cohort study. Heart 2010;96;1401-6.
65. Barst RJ, Ivy D, Dingemanse J, Widlitz A, Schmitt K, Doran A, Bingaman D, Nguyen N, Gaitonde M, van Giersbergen PL. Pharmacokinetics, safety and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003;73;372-82. (Pubitemid 36403597)
66. Beghetti M, Haworth SG, Bonnet D, et al. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study. Br J Clin Pharmacol 2009; 68:948-55.
67. Rosenzweig EB, Ivy DD, Wildlitz A, Doran A, Claussen LR, Yung d, Abman SH, Morganti A, Nguyen N, Barst RJ. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 2005;46;697-704. (Pubitemid 41132700)